Macrocyclic inhibitors of BCL proteins
View Patent ↗Macrocyclic compounds of formula (I), in which B 1 and X 1 taken together are alkylene which is unsubstituted or substituted with ═O and having one CH 2 moiety unreplaced or replaced with CH═CH, O, NH or N(alkyl), which inhibit the activity of antiapoptotic Bcl-2 family protein members, compositions containing the compounds and methods of treating diseases during which are expressed one or more than one of an anti-apoptotic family protein member are disclosed.
1. A compound having formula (I),
or a therapeutically acceptable salt thereof, wherein
A 1 is CN, NO 2 , C(O)OH, F, Cl, Br, CF 3 , OCF 3 , CF 2 CF 3 , OCF 2 CF 3 , C(O)R 1 , C(O)OR 1 , SR 1 , C(O)NH 2 , C(O)NHR 1 , C(O)N(R 1 ) 2 , NHS(O)R 1 , SO 2 NHR 1 , S(O)R 1 , or SO 2 R 1 ;
n is 1, 2 or 3;
R 1 is R 2 , R 3 , R 4 or R 5 ;
R 2 is alkyl, alkenyl or alkynyl;
R 3 is perhaloalkyl or perhaloalkenyl;
R 4 is C 1 -alkyl or C 2 -alkenyl, each of which is unsubstituted or substituted with one or two of independently selected F, Cl or Br;
R 5 is C 2 -C 6 -alkyl or C 3 -C 6 -alkenyl, each of which is unsubstituted or substituted with one or two or three or four of independently selected F, Cl or Br;
B 1 and X 1 taken together are alkylene, unsubstituted or substituted with ═O and having one CH 2 moiety unreplaced or replaced with CHCH, O, NH or N(alkyl);
D 1 is H, alkyl or phenyl;
Z 1 is Z 2 , Z 3 or Z 4 ;
Z 2 is phenyl or heteroaryl, each of which is substituted with R 6 , OR 6 , SR 6 , S(O)R 6 or SO 2 R 6 ;
R 6 is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unsubstituted or substituted with one or two of independently selected alkyl, spiroalkyl, F, Cl, Br, I, R 7 , OR 7 , SR 7 , S(O)R 7 , or SO 2 R 7 ;
R 7 is alkyl, alkenyl or alkynyl;
Z 3 is phenyl or heteroaryl, each of which is substituted with cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is substituted with CHR 8 ;
R 8 is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unsubstituted or substituted with one or two or three of independently selected F, Cl, Br, I, OH, C(O)OH, C(O)OCH 3 , CN, NH 2 , NH(CH 3 ), N(CH 3 ) 2 , CF 3 , OCF 3 , CF 2 CF 3 or OCF 2 CF 3 ;
Z 4 is phenyl or heteroaryl, each of which is substituted with phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is substituted with one or two of R 9 or OR 9 ;
R 9 is alkyl, alkenyl or alkynyl, each of which is substituted with one or two of independently selected phenyl, heteroaryl cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unsubstituted or substituted with one or two or three of independently selected alkyl, alkenyl, alkynyl, F, Cl, Br, I, OH, C(O)OH, C(O)OCH 3 , CN, NH 2 , NH(CH 3 ), N(CH 3 ) 2 , CF 3 , OCF 3 , CF 2 CF 3 , OCF 2 CF 3 or R 11 ; and
R 11 is phenyl or heteroaryl, each of which is unsubstituted or substituted with one or two or three of F, Cl, Br, I, OH, C(O)OH, C(O)OCH 3 , CN, NH 2 , NH(CH 3 ), N(CH 3 ) 2 , CF 3 , OCF 3 , CF 2 CF 3 , OCF 2 CF 3 .
2. The compound of claim 1 wherein A 1 is NO 2 ; n is 1, 2 or 3;
B 1 and X 1 together are alkylene, which is unsubstituted or substituted with ═O and having one CH 2 moiety unreplaced or replaced with CHCH, O, NH or N(alkyl);
D 1 is H, alkyl or phenyl;
Z 1 is Z 2 , Z 3 or Z 4 ;
Z 2 is phenyl substituted with R 6 , OR 6 , SR 6 , S(O)R 6 or SO 2 R 6 ;
R 6 is phenyl or heterocycloalkyl, each of which is unsubstituted or substituted with one or two of independently selected alkyl, spiroalkyl, F, Cl, Br or I;
Z 3 is phenyl substituted with heterocycloalkyl which is substituted with CHR 8 ;
R 8 is phenyl substituted with one or two or three of independently selected F, Cl, Br, I, OH, C(O)OH, C(O)OCH 3 , CN, NH 2 , NH(CH 3 ), N(CH 3 ) 2 , CF 3 , OCF 3 , CF 2 CF 3 or OCF 2 CF 3 ;
Z 4 is phenyl substituted with heterocycloalkyl which is substituted with one or two of R 9 or OR 9 ;
R 9 is alkyl or alkenyl, each of which is substituted with one or two of independently selected phenyl, cycloalkenyl or heterocycloalkenyl, each of which is unsubstituted or substituted with one or two or three of independently selected alkyl, alkenyl, alkynyl, F, Cl, Br, I, OH, C(O)OH, C(O)OCH 3 , CN, NH 2 , NH(CH 3 ), N(CH 3 ) 2 , CF 3 , OCF 3 , CF 2 CF 3 or R 11 ; and
R 11 is phenyl which is unsubstituted or substituted with one or two or three of F, Cl, Br, I, OH, C(O)OH, C(O)OCH 3 , CN, NH 2 , NH(CH 3 ), N(CH 3 ) 2 , CF 3 , OCF 3 , CF 2 CF 3 , OCF 2 CF 3 .
3. The compound of claim 2 , wherein A 1 is NO 2 ; n is 1; B 1 and X 1 taken together are alkylene substituted with ═O and having one CH 2 moiety replaced with O;
D 1 is alkyl;
Z 1 is Z 2 , Z 3 or Z 4 ;
Z 2 is phenyl substituted with R 6 or OR 6 ;
R 6 is phenyl, piperidinyl or piperazinyl, each of which is unsubstituted or substituted with one or two of independently selected alkyl, spiroalkyl, F, Cl, Br or I;
Z 3 is phenyl substituted with heterocycloalkyl which is substituted with CHR 8 ;
R 8 is phenyl substituted with one or two or three of independently selected F, Cl, Br, I, CF 3 or OCF 3 ;
Z 4 is phenyl substituted with piperidinyl or piperazinyl, each of which is substituted with one or two of R 9 or OR 9 ;
R 9 is alkyl or alkenyl, each of which is substituted with one or two of independently selected phenyl, cycloalkenyl or heterocycloalkenyl, each of which is unsubstituted or substituted with one or two or three of independently selected alkyl, alkenyl, alkynyl, F, Cl, Br, I, OH, C(O)OH, C(O)OCH 3 , CN, NH 2 , NH(CH 3 ), N(CH 3 ) 2 , CF 3 , OCF 3 or R 11 ; and
R 11 is phenyl which is unsubstituted or substituted with one or two or three of F, Cl, Br, I, OH, CF 3 or OCF 3 .
4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
(2R)-N-(4-(4,4-dimethylpiperidin-1-yl)benzoyl)-5-methyl-13-nitro-9-oxo-2-((phenylsulfanyl)methyl)-1,2,3,4,5,6,7,9-octahydro-8,1,5-benzoxadiazacycloundecine-11-sulfonamide;
(2R)-N-(4-(4-((2-(4-chlorophenyl)-1-cyclohexen-1-yl)methyl)piperazin-1-yl)benzoyl)-5-methyl-13-nitro-9-oxo-2-((phenylsulfanyl)methyl)-1,2,3,4,5,6,7,9-octahydro-8,1,5-benzoxadiazacycloundecine-11-sulfonamide;
(2R)-N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-5-methyl-13-nitro-9-oxo-2-((phenylsulfanyl)methyl)-1,2,3,4,5,6,7,9-octahydro-8,1,5-benzoxadiazacycloundecine-11-sulfonamide;
(2R)-N-(4-(8-azaspiro[4.5]dec-8-yl)benzoyl)-5-methyl-13-nitro-9-oxo-2-((phenylsulfanyl)methyl)-1,2,3,4,5,6,7,9-octahydro-8,1,5-benzoxadiazacycloundecine-11-sulfonamide;
(2R)-5-methyl-13-nitro-9-oxo-2-((phenylsulfanyl)methyl)-N-(4-(4-(2-(trifluoromethyl)benzylidene)piperidin-1-yl)benzoyl)-1,2,3,4,5,6,7,9-octahydro-8,1,5-benzoxadiazacycloundecine-11-sulfonamide;
(2R)-N-((4′-fluoro(1,1′-biphenyl)-4-yl)carbonyl)-5-methyl-13-nitro-9-oxo-2-((phenylsulfanyl)methyl)-1,2,3,4,5,6,7,9-octahydro-8,1,5-benzoxadiazacycloundecine-11-sulfonamide;
(2R)-N-(4-(4-methoxy-4-((Z)-2-phenylethenyl)piperidin-1-yl)benzoyl)-5-methyl-13-nitro-9-oxo-2-((phenylsulfanyl)methyl)-1,2,3,4,5,6,7,9-octahydro-8,1,5-benzoxadiazacycloundecine-11-sulfonamide;
(2R)-N-(4-(4-(2-fluorobenzyl)-4-methoxypiperidin-1-yl)benzoyl)-5-methyl-13-nitro-9-oxo-2-((phenylsulfanyl)methyl)-1,2,3,4,5,6,7,9-octahydro-8,1,5-benzoxadiazacycloundecine-11-sulfonamide;
(2R)-N-(4-(4-((1,1′-biphenyl)-2-ylmethyl)-4-methoxypiperidin-1-yl)benzoyl)-5-methyl-13-nitro-9-oxo-2-((phenylsulfanyl)methyl)-1,2,3,4,5,6,7,9-octahydro-8,1,5-benzoxadiazacycloundecine-11-sulfonamide;
(2R)-N-(4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-5-methyl-13-nitro-9-oxo-2-((phenylsulfanyl)methyl)-1,2,3,4,5,6,7,9-octahydro-8,1,5-benzoxadiazacycloundecine-11-sulfonamide;
(2R)-N-(4-(4-((2-(4-chlorophenyl)cyclohept-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-5-methyl-13-nitro-9-oxo-2-((phenylsulfanyl)methyl)-1,2,3,4,5,6,7,9-octahydro-8,1,5-benzoxadiazacycloundecine-11-sulfonamide;
(2R)-N-(4-(4-(3,3-diphenyl-2-propenyl)piperazin-1-yl)benzoyl)-5-methyl-13-nitro-9-oxo-2-((phenylsulfanyl)methyl)-1,2,3,4,5,6,7,9-octahydro-8,1,5-benzoxadiazacycloundecine-11-sulfonamide;
(2R)-N-(4-(4-((1,1′-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-5-methyl-13-nitro-9-oxo-2-((phenylsulfanyl)methyl)-1,2,3,4,5,6,7,9-octahydro-8,1,5-benzoxadiazacycloundecine-11-sulfonamide;
(2R)-5-methyl-13-nitro-9-oxo-2-((phenylsulfanyl)methyl)-N-(4-(4-(2-(trifluoromethyl)benzyl)piperazin-1-yl)benzoyl)-1,2,3,4,5,6,7,9-octahydro-8,1,5-benzoxadiazacycloundecine-11-sulfonamide;
(2R)-N-(4-(4-((2-(4-chlorophenyl)-4,4-diethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-5-methyl-13-nitro-9-oxo-2-((phenylsulfanyl)methyl)-1,2,3,4,5,6,7,9-octahydro-8,1,5-benzoxadiazacycloundecine-11-sulfonamide;
(2R)-N-(4-(4-((4-(4-chlorophenyl)-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-1-yl)benzoyl)-5-methyl-13-nitro-9-oxo-2-((phenylsulfanyl)methyl)-1,2,3,4,5,6,7,9-octahydro-8,1,5-benzoxadiazacycloundecine-11-sulfonamide;
(2R)-5-methyl-13-nitro-9-oxo-N-(3-phenoxybenzoyl)-2-((phenylsulfanyl)methyl)-1,2,3,4,5,6,7,9-octahydro-8,1,5-benzoxadiazacycloundecine-11-sulfonamide; and
(2R)-N-(4-(4-((2-(4-chlorophenyl)-1-cyclohexen-1-yl)methyl)piperazin-1-yl)benzoyl)-5-methyl-14-nitro-10-oxo-2-((phenylsulfanyl)methyl)-1,3,4,5,6,7,8,10-octahydro-2H-9,1,5-benzoxadiazacyclododecine-12-sulfonamide.